Sep. 15
Prescription
Sertraline / Zoloft prescribed.
25 mg was prescribed with a planned increase after one week. Later testimony placed actual start about a month after the prescription date.
EV-MED-0018, 0020THE CLANCY RECORDS · FACTUAL / EVIDENTIARY MATRIX
Medication Matrix.
MED-PRE v1.1 asks a narrower question than a medication-name list: what does the evidentiary record actually establish about prescribing, availability, reported use, supported exposure, dose, adherence, efficacy, adverse-effect reporting, provider response, objective evidence, and unresolved gaps before January 24, 2023?
Validated source stateMED-PRE-v1.1-VALIDATED
Version dateAugust 27, 2026
Publication statusSEALED · editorial/source-map QC complete
The governing rule:
Prescribed ≠ dispensed ≠ possessed ≠ taken ≠ taken as directed ≠ therapeutically exposed ≠ caused a symptom.
Prescribed ≠ dispensed ≠ possessed ≠ taken ≠ taken as directed ≠ therapeutically exposed ≠ caused a symptom.
HOW TO READ THIS AUDIT
A drug name is not an exposure state.
Why medication count can mislead
The record includes serial trials, PRN medications, very short exposures, discontinued or accumulated prescriptions, proposed treatments, planned dose increases, over-the-counter products, historical medications, and medications whose actual pre-event ingestion is not established. These are not equivalent exposure states.
Reported does not mean independently proven
If Lindsay reported an effect, the audit records that the report occurred. If a provider, collateral witness, toxicology result, pill count, or physical record independently adds information, that is tracked separately.
Propagation is not corroboration
Repeating the same originating report in later medical records, testimony, or expert analysis does not create a second independent event unless the later source supplies independent evidence.
How to verify the work
Each medication entry traces backward through its publication classification to canonical Evidence IDs, Source IDs, representative pinpoints, and a reader note. The proof chain is public-facing; internal exploratory prompts, discarded hypotheses, and operational research machinery are not part of the evidentiary proof.
MEDICATION EVENT TIMELINE
See the treatment sequence, not just the medication names.
This visual plots selected dated anchors already contained in the sealed MED-PRE v1.1 evidence ledger. It is designed to show spacing, clustering, treatment changes, reported effects, provider responses, and objective anchors across the pre-event period.
Visual rule: a point means the record places an event at or within the labeled date window. It does not by itself mean a medication was ingested, taken continuously, taken as directed, or caused a reported effect. Duration is shown only where the sealed record supports a bounded interval.
Oct. 20
Report + response
Zoloft-period effects were reported; Zoloft was stopped.
The contemporaneous report included worsened sleep and other symptoms. The report is preserved as self-report; medication-specific causation was not independently established.
EV-MED-0019, 0063, 0064Oct. 26
Treatment plan
Buspirone and hydroxyzine entered the treatment plan.
Buspirone was scheduled at low dose; hydroxyzine was PRN, with Ativan still available for extreme anxiety. Later bottle counts showed very limited depletion from the Oct. 26 fills.
EV-MED-0030–0033, 0053Nov. 16+
Reported use
Trazodone entered the sleep-treatment sequence.
After an emergency-room visit, Lindsay reported trazodone helped her fall asleep but did not fully resolve sleep maintenance.
EV-MED-0034Nov. 25
Brief exposure
Ambien was used as a one-time trial.
Provider testimony supports a single trial. A later proposal for a higher or controlled-release option was not accepted and is not a second exposure.
EV-MED-0070Nov. 27
Combination report
Remeron + Klonopin report; Klonopin described as two nights.
The same communication reported good sleep and feeling disconnected. The combination prevents assigning the reported effect to either medication alone.
EV-MED-0013–0016Nov. 29 / early Dec.
Provider response
Valium was selected as the longer-acting benzodiazepine strategy.
The provider rationale responded to reported rebound-anxiety concerns and a taper strategy; that response is not independent proof of the reported causal phenomenon.
EV-MED-0057Dec. 7
Treatment plan
Seroquel titration plan documented.
The plan moved from 100 toward 400 mg. The plan itself is not evidence that 400 mg was taken.
EV-MED-0004, 0058Dec. 8
Combination report
Valium + Seroquel was reported as helping sleep.
The same period also contains a reported dependence concern during the Valium taper. Benefit and concern remain separate propositions.
EV-MED-0059, 0060Dec. 9
Dose instruction
Valium continuation and divided-dose instruction.
The provider described 5 mg tablets with one-half tablet twice daily as the temporary instruction during the treatment episode.
EV-MED-0049, 0061Dec. 12
Reported exposure
200 mg Seroquel reported—not the planned 400 mg.
The same communication described deep sleep on Valium + Seroquel and daytime depression/unmotivation, preserving both positive and negative reports without converting either into medication-specific causation.
EV-MED-0005, 0006, 0047, 0048Dec. 16
Prescription / plan
Lamictal 25 mg was recommended and relayed across providers.
The sealed classification remains prescribed/ordered; actual pre-event ingestion is not established. The slow-titration framework is a plan, not dose history.
EV-MED-0038–0040Late Dec.
Provider response
Women & Infants recommended tapering Seroquel from 200 mg.
The record also preserved patient attribution of insomnia/mental numbness to Seroquel while the facility used rule-out—not confirmed-causation—language for adverse drug effects.
EV-MED-0044–0046, 0051Jan. 6
Report + response
Trazodone continued amid broken sleep.
The record described about five broken hours of sleep rather than zero sleep, and trazodone was increased.
EV-MED-0035Jan. 9–12
Prescription / inventory
Diazepam 5 mg and trazodone 150 mg fills entered the January record.
Later physical counts constrain depletion but do not prove who ingested missing tablets, when, or according to what exact schedule.
EV-MED-0036, 0037, 0041Jan. 16
Prescription
Amitriptyline 10 mg prescribed; diazepam 2 mg fill also documented.
The diazepam label detail remained unresolved. Amitriptyline exposure was later strongly bounded by the physical count.
EV-MED-0001, 0042Jan. 20
Digital artifact
Post-exposure Seroquel search artifact.
The dated search occurred after Seroquel had been tapered/discontinued and is therefore not treated as a contemporaneous adverse-effect report under active exposure.
EV-MED-0052Jan. 23
Dose authorization
Amitriptyline increase to 20 mg was authorized.
Authorization is not established ingestion. The next day's physical count did not support the additional tablet required for a 20 mg pre-event dose.
EV-MED-0002, 0003Jan. 24
Objective boundary
Physical inventory and toxicology constrain the endpoint.
Bottle counts and toxicology provide objective anchors at the event boundary while preserving timing, administration, and ingestion limitations.
EV-MED-0003, 0012, 0023, 0024, 0037, 0041, 0042EXPOSURE SCALE
Five grades; different evidentiary states.
E1Strongly bounded exposure.
E2Meaningful supported exposure.
E3Brief or limited exposure.
E4Prescribed or available; meaningful exposure uncertain.
E0Exposure not established.
SUPPORTEDREPORTEDOBSERVEDOBJECTIVE CONSTRAINTUNRESOLVEDEXCLUDED
PUBLIC MEDICATION MATRIX · 22 FAMILIES
The publication source state.
Open any medication to see the reader-facing evidence fields and public proof chain. A classification describes what the reviewed record supports; it is not a diagnosis or causal verdict.
Sertraline / ZoloftBrief supported trialE3
Effect / efficacy provenance
Adverse effects / worsened sleep principally Lindsay self-report
Independent / objective anchor
Prescription + short-course evidence
Provider conclusion / response
Tufts remembered reported effects as non-concerning
Conflict / tension
Causal severity not independently established
Open gap
Exact dose-by-dose ingestion
Frozen note
Do not state Zoloft objectively caused insomnia
Evidence IDs
EV-MED-0018, 0019, 0020, 0063, 0064
Source IDs
SRC-TR-D10
Representative pinpoints
~46:15–46:46; ~56:58–57:30; ~03:19:34–03:19:56
Prescription/start/dose plan is distinct from patient-reported adverse effects and medication-specific causation.
Fluoxetine / ProzacBrief 2022 exposureE3
Effect / efficacy provenance
Worsened sleep = Lindsay report; earlier exposure reportedly helpful/no side effects
Independent / objective anchor
Prescription/exposure history
Provider conclusion / response
Stopped after reported poor tolerance
Conflict / tension
Different exposure episodes prevent universal causation claim
Open gap
GAP-MED-003
Frozen note
Exact 2022 count/duration unresolved
Evidence IDs
EV-MED-0065, 0066
Source IDs
SRC-TR-D10; SRC-TR-D9
Representative pinpoints
D10 ~03:18:00–03:18:44; D9 ~04:07:54 and ~04:11:19–04:13:11
Historical nursing-school experience and 2022 postpartum trial are separate exposure epochs.
Mirtazapine / RemeronSupported under differing combinationsE2/E3 context-dependent
Effect / efficacy provenance
Sleep benefit, disconnection, limited efficacy are combination-specific Lindsay reports
Independent / objective anchor
Prescription history + contemporaneous communications
Provider conclusion / response
Paul treated causation as possible, not certain
Conflict / tension
Do not attribute combination effects to Remeron alone
Open gap
None material beyond combination chronology
Frozen note
Separate Remeron+Klonopin from Remeron+CBD and reportedly untaken combinations
Evidence IDs
EV-MED-0013, 0015, 0017, 0062
Source IDs
SRC-TR-D10; SRC-TR-D9
Representative pinpoints
D10 ~04:33:38–04:34:33; ~04:36:46–04:36:56; D9 ~04:11:19–04:12:09
Combination-specific reports cannot be assigned to Remeron alone.
Clonazepam / KlonopinVery briefE3
Effect / efficacy provenance
Disconnection during combination = self-report
Independent / objective anchor
Two-night contemporaneous report; authoritative Klonopin pill inventory not reproduced
Provider conclusion / response
Paul saw no issue stopping after two days
Conflict / tension
Later broad dependence narrative must respect exposure boundary
Open gap
VAL-MED-007 — authoritative Klonopin pill count unresolved
Frozen note
Reported exposure very brief; do not use derivative 11.5/14 until authoritative source is reproduced
Evidence IDs
EV-MED-0013, 0014, 0015, 0016, 0062
Source IDs
SRC-TR-D10; SRC-TR-D9
Representative pinpoints
D10 ~04:33:38–04:34:40; D9 ~04:11:19–04:12:09
Two-night contemporaneous report controls. The unverified 14/11.5 pill count is excluded.
Quetiapine / SeroquelMeaningful supported exposureE2
Effect / efficacy provenance
Sleep benefit + later depression/spacey/hangover/conversation/HR concerns; most adverse effects self-report
Independent / objective anchor
Provider-recognized sleep improvement; titration/report mismatch
Provider conclusion / response
Jolotta treated sleep/manic-type symptoms; later taper at McLean
Conflict / tension
Simple Seroquel-caused-depression claim in tension with longitudinal chronology
Open gap
GAP-MED-005; GAP-MED-006
Frozen note
Do not equate planned 400 mg with established actual dose
Evidence IDs
EV-MED-0004, 0005, 0006, 0046–0052, 0073
Source IDs
SRC-TR-D11; D10; D20; D13; D21-WHISPER
Representative pinpoints
D11 ~02:13:59; ~02:26:10–02:26:25; D20 ~03:41:25–03:41:46; D21 ~44:48–47:16
Treatment-plan ceiling, reported dose, benefit, adverse reports, and later search artifact remain separate propositions.
Lorazepam / AtivanSupported intermittent/PRN exposureE2
Effect / efficacy provenance
Rebound anxiety/dependence concerns = Lindsay reports
Independent / objective anchor
Prescription history + lorazepam in toxicology
Provider conclusion / response
Provider used longer-acting/taper strategy
Conflict / tension
Withdrawal/dependence not established by patient language
Open gap
GAP-MED-002
Frozen note
Toxicology attribution limited by exact MAR/specimen timing
Evidence IDs
EV-MED-0011, 0023, 0024, 0053–0057
Source IDs
SRC-TR-D11; D7; D9
Representative pinpoints
D11 ~52:01–52:05; D7 ~32:55–33:29 and ~54:46–55:35; D9 ~03:55:43–03:55:59
Toxicology anchors exposure; rebound/dependence language remains patient-originating and timing-limited.
Diazepam / ValiumMeaningful taper exposureE2
Effect / efficacy provenance
Feeling dependent/panic/slower taper requests = Lindsay reports
Independent / objective anchor
Pill counts + diazepam/metabolites in toxicology + CIWA
Provider conclusion / response
Jolotta continued taper; interpreted concern as anxiety about dependence
Conflict / tension
CIWA 1 = minimal-to-no withdrawal at tested encounter
Open gap
GAP-MED-001; GAP-MED-002
Frozen note
Taper does not itself establish addiction/withdrawal
Evidence IDs
EV-MED-0008–0010, 0023, 0024, 0041, 0042, 0057–0061
Source IDs
SRC-TR-D11; D7; D12
Representative pinpoints
D11 ~02:02:35–02:04:38 and ~02:16:46–02:20:00; D12 ~17:28–17:59
Pill counts and toxicology constrain exposure; CIWA score 1 is encounter-specific.
TrazodoneSupported availability/useE2
Effect / efficacy provenance
Limited efficacy principally self-report
Independent / objective anchor
Jan. bottle count 30 dispensed / 20 remaining
Provider conclusion / response
Adjusted for continuing reported sleep difficulty
Conflict / tension
No objective trazodone-specific sleep failure located
Open gap
Exact nightly ingestion
Frozen note
10 absent tablets do not prove timing or ingestion identity
Evidence IDs
EV-MED-0034–0037
Source IDs
SRC-TR-D10; D12
Representative pinpoints
D10 ~04:06:10–04:06:27 and ~02:54:00–02:55:37; D12 ~16:45–17:22
Reported partial sleep benefit and 30/20 bottle count are separate evidence types.
AmitriptylineStrongly bounded 10 mg schedule through Jan. 23E1
Effect / efficacy provenance
No major adverse-effect proposition required
Independent / objective anchor
30 dispensed / 22 remaining = 8 absent
Provider conclusion / response
20 mg increase authorized Jan. 23
Conflict / tension
Physical count does not support extra tablet for 20 mg before event
Open gap
None material
Frozen note
Authorized dose increase ≠ supported higher-dose exposure
Evidence IDs
EV-MED-0001–0003
Source IDs
SRC-TR-D10
Representative pinpoints
~02:55:41; ~03:39:01–03:40:24
Authorization to increase dose is not evidence that the higher dose was ingested.
Lamotrigine / LamictalPrescribed/ordered; actual pre-event ingestion not established. Day 21 provisional testimony indicates filled but not taken; final classification does not rely on that negation pending Rev/audio.E4/E0 boundary
Effect / efficacy provenance
No patient-specific Lamictal adverse effect established; rash discussion is general risk counseling, not an experienced reaction.
Independent / objective anchor
Order/prescription history; Day 21 fill/non-use testimony remains retrospective and provisional in the sealed v1.1 source state.
Provider conclusion / response
25 mg starting plan with slow titration discussed; actual progression not supported.
Conflict / tension
Do not convert prescription, fill, or titration discussion into ingestion.
Open gap
GAP-MED-009 — final Rev/audio check of Day 21 fill/non-use wording.
Frozen note
PUBLICATION-SAFE CORE STATE: prescribed/ordered; actual pre-event ingestion not established. Provisional Day 21 non-use may be footnoted but is not required for the classification.
Evidence IDs
EV-MED-0038–0040, 0071, 0072
Source IDs
SRC-TR-D10; D11; D21-WHISPER
Representative pinpoints
D10 ~02:46:07–02:46:12; D11 ~02:47:12–02:49:49; D21 ~02:11:58–02:13:00
Day 21 non-use wording remains provisional in the sealed source state; the core classification does not depend on it. A Rev Day 21 working transcript became available August 27 and is recorded below for later versioned reconciliation.
Buspirone / BuSparPrescribed; limited sustained exposure evidence for some fillsE4
Effect / efficacy provenance
Efficacy/adverse-effect chronology incomplete
Independent / objective anchor
Near-full / minimally depleted bottle evidence
Provider conclusion / response
Chosen as comparatively mild anxiety treatment
Conflict / tension
Prescription history cannot establish sustained use
Open gap
GAP-MED-004
Frozen note
Do not count equally with meaningful exposure drugs
Evidence IDs
EV-MED-0030, 0031
Source IDs
SRC-TR-D9; SRC-TR-OPEN
Representative pinpoints
D9 ~03:57:38–03:59:09; mixed source later testimony ~02:57:04–02:57:28
EV-MED-0031 uses later Patrick Clancy testimony in the mixed Opening Statements file, not opening argument.
HydroxyzinePRN; limited exposureE3/E4
Effect / efficacy provenance
No independently observed adverse reaction located
Independent / objective anchor
27/30 remaining
Provider conclusion / response
Offered as non-benzodiazepine option
Conflict / tension
Sustained use unsupported
Open gap
GAP-MED-004
Frozen note
3 absent tablets do not prove 3 ingestions
Evidence IDs
EV-MED-0032, 0033
Source IDs
SRC-TR-D9; SRC-TR-OPEN
Representative pinpoints
D9 ~03:59:11–04:00:52; mixed source later testimony ~02:57:28–02:58:05
Three absent tablets do not prove three ingestions; source segment is later witness testimony, not opening argument.
Diphenhydramine / BenadrylOTC reported exposureE4
Effect / efficacy provenance
Reported helpful with Ativan
Independent / objective anchor
Historical regimen evidence
Provider conclusion / response
Later stopped during regimen change
Conflict / tension
No objective sleep-effect measurement located
Open gap
Exact dosing
Frozen note
Not a separate psychiatric prescription
Evidence IDs
EV-MED-0054, 0058, 0066
Source IDs
SRC-TR-D9; D11
Representative pinpoints
D9 ~04:11:18–04:13:11; D11 ~02:08:41–02:10:10
Ancillary OTC use; combination effects should not be assigned to Benadryl alone.
MelatoninKnown OTC/supplement regimen itemE4
Effect / efficacy provenance
No material adverse-effect issue identified
Independent / objective anchor
Regimen documentation
Provider conclusion / response
Supportive sleep agent
Conflict / tension
N/A
Open gap
Minor
Frozen note
Do not inflate psychiatric prescription count
Evidence IDs
EV-MED-0058
Source IDs
SRC-TR-D11
Representative pinpoints
~02:08:41 and ~02:09:23–02:10:10
Included as ancillary co-exposure, not a psychiatric-prescription count.
CBDAncillary co-exposure reportedE4
Effect / efficacy provenance
Relevant to Remeron efficacy report
Independent / objective anchor
Contemporaneous report
Provider conclusion / response
No provider causal conclusion required
Conflict / tension
Confounds attribution to Remeron alone
Open gap
Exact product/dose
Frozen note
Treat as ancillary exposure, not psychiatric prescription
Evidence IDs
EV-MED-0017
Source IDs
SRC-TR-D10
Representative pinpoints
~04:36:46–04:36:56
Relevant because it confounds attribution of the Remeron efficacy report.
Aripiprazole / AbilifyPrimary-record exposure not establishedE0
Effect / efficacy provenance
Appears in later consultant/litigation medication list
Independent / objective anchor
No primary exposure anchor yet
Provider conclusion / response
N/A
Conflict / tension
Later list must not silently create exposure
Open gap
GAP-MED-007
Frozen note
Do not count as established pre-event exposure
Evidence IDs
No positive primary exposure atom; GAP-MED-007 controls
Source IDs
Later medication-list evidence only
Representative pinpoints
See validated Gap Register
Absence of a primary exposure anchor is preserved as E0, not converted into proof of non-use.
Bupropion / WellbutrinHistorical exposure reported; postpartum-period exposure not establishedHistorical only
Effect / efficacy provenance
Reported effective and no side effects in historical intake
Independent / objective anchor
Treating-provider testimony reviewing intake history
Provider conclusion / response
No 2022–Jan. 24 treatment course identified
Conflict / tension
Historical success cannot establish postpartum exposure
Open gap
Exact historical duration/fill not material to MED-PRE
Frozen note
Keep historical-only; do not count in postpartum medication total
Evidence IDs
EV-MED-0065, 0067
Source IDs
SRC-TR-D10
Representative pinpoints
~03:18:00–03:18:44; Julie Paul ~04:16:05–04:16:16
Historical positive report is not a 2022–Jan. 24 exposure.
PropranololHistorical trial reported; no meaningful 2022–Jan. 24 course establishedHistorical only
Effect / efficacy provenance
Reported as one of medications she did well on in nursing school
Independent / objective anchor
Treating-provider testimony reviewing historical history
Provider conclusion / response
No pre-event dose/fill/adherence course located
Conflict / tension
Day 19 occasional current use is post-event and must not backfill MED-PRE
Open gap
Exact historical dose/duration
Frozen note
Historical-only family; post-event/current propranolol expressly excluded from MED-PRE
Evidence IDs
EV-MED-0068
Source IDs
SRC-TR-D10
Representative pinpoints
Julie Paul ~04:16:05–04:16:16
Later/current use is post-event and excluded from MED-PRE.
Escitalopram / LexaproCollateral recollection only; primary pre-event exposure not establishedE0
Effect / efficacy provenance
Amy Bevins remembered an earlier medication discussed by Lindsay as Lexapro; no clean medication-specific efficacy/adverse-effect origin established
Independent / objective anchor
No treating-provider/pharmacy/inventory anchor located
Provider conclusion / response
N/A
Conflict / tension
Later dark-thought disclosure was temporally separate in Bevins testimony and cannot be attributed to Lexapro
Open gap
GAP-MED-010
Frozen note
Primary pre-event exposure not established
Evidence IDs
EV-MED-0069
Source IDs
SRC-TR-D8
Representative pinpoints
~43:09–44:54
Medication-name recollection does not establish prescription, fill, ingestion, or causation.
Zolpidem / AmbienOne-time Nov. 25 trial; later continuation proposal declinedE3
Effect / efficacy provenance
No clean efficacy/adverse-effect result established from provider testimony reviewed
Independent / objective anchor
Treating-provider testimony: Paul one-time dose; Jolotta knew ~5 mg had been tried
Provider conclusion / response
Jolotta considered 10 mg or controlled-release Ambien for middle-of-night wakeups; Lindsay was not receptive
Conflict / tension
One-time 5 mg trial must not be flattened into sustained medication exposure; later proposal is not ingestion
Open gap
Exact ingestion/effect not independently measured
Frozen note
Later continuation proposal was declined
Evidence IDs
EV-MED-0070
Source IDs
SRC-TR-D10; D11
Representative pinpoints
D10 ~04:28:50 onward; D11 ~50:16–51:06
Later proposal is not a second exposure.
Olanzapine / ZyprexaProposed in Dec. 2022; pre-event exposure not established; Day 21 says current/post-event useE0 pre-event
Effect / efficacy provenance
No pre-event efficacy/adverse-effect attribution established from Day 21
Independent / objective anchor
No pre-event fill/admin/ingestion anchor in reconciled source; testimony says Seroquel + Valium were continued instead
Provider conclusion / response
Jolotta proposal was not selected in Dec.; later/current use belongs to post-event comparator
Conflict / tension
Medication-name presence could falsely inflate pre-event exposure count
Open gap
None beyond final transcript wording check
Frozen note
Exclude current/post-event olanzapine use from MED-PRE
Evidence IDs
EV-MED-0074
Source IDs
SRC-TR-D21-WHISPER
Representative pinpoints
~42:57–44:20
Do not backfill later/current use into pre-event exposure.
LithiumPossible actual exposure referenced by Day 21 expert; temporal locus unresolvedE0 for MED-PRE pending locus
Effect / efficacy provenance
No patient-specific pre-event effect/efficacy proposition can be assigned until date/facility is known
Independent / objective anchor
No pre-event pharmacy/MAR anchor located in this passage
Provider conclusion / response
Day 21 expert appears to reference prior use, but the sealed Whisper source loses where/when
Conflict / tension
1200 mg twice-daily lithium was a hypothetical toxicity example, not her dose
Open gap
GAP-MED-011
Frozen note
Do not count lithium as MED-PRE exposure unless Rev/audio resolves the locus into the pre-event period
Evidence IDs
EV-MED-0075, 0076
Source IDs
SRC-TR-D21-WHISPER
Representative pinpoints
~45:11–45:55
1,200 mg twice daily was hypothetical, not a patient-specific dose.
SOURCE MAP
The public source path.
The links below are the source documents identified by the sealed publication package. They are provided so the reader can move from a medication finding to its Source ID and then to the underlying public record. Source limitations remain part of the proof.
| Source ID | Source / public copy | Role in MED-PRE | Authority / limitation |
|---|---|---|---|
| SRC-TR-D2 | MA v. Lindsay Clancy Day 2 | Rev.pdf | Collateral firsthand testimony, including insomnia footprint | Primary trial testimony; retrospective as to pre-event observations |
| SRC-TR-D7 | MA v. Lindsay Clancy Day 7 | Rev.pdf | Toxicology/laboratory testimony and interpretation | Primary laboratory testimony plus expert interpretation; timing limitations preserved |
| SRC-TR-D8 | MA v. Lindsay Clancy Day 8 | Rev.pdf | Collateral testimony and medication-history references | Primary trial testimony; collateral recollection is not primary exposure proof |
| SRC-TR-D9 | MA v. Lindsay Clancy Day 9 | Rev.pdf | Provider-observation/treatment evidence | Primary trial testimony; exact proposition/witness remains atom-specific |
| SRC-TR-D10 | MA v. Lindsay Clancy Day 10 | Rev.pdf | Tufts, Julie Paul, provider history, pill-count and medication-event testimony | Primary trial testimony; underlying records/exhibits partly embedded |
| SRC-TR-D11 | MA v. Lindsay Clancy Day 11 | Rev.pdf | Jolotta, MyChart, benzodiazepine/taper and medication chronology | Primary trial testimony quoting/reviewing contemporaneous records |
| SRC-TR-D12 | MA v. Lindsay Clancy Day 12 | Rev.pdf | Physical evidence / medication inventory chain | Primary evidence-handling testimony |
| SRC-TR-D13 | MA v. Lindsay Clancy Day 13.pdf | Trial testimony used by one canonical medication atom | Primary trial testimony; proposition-level classification controls |
| SRC-TR-D20 | Archived Day 20 Rev PDF Current Rev working transcript | Retrospective expert interpretation and embedded review of clinical records | Expert testimony; underlying clinical records remain analytically distinct. Rev direct transcript published Aug. 26, 2026. |
| SRC-TR-D21-WHISPER | Whisper source used by sealed v1.1 audit Newer Rev working transcript | Provisional Day 21 reconciliation and false-positive controls | Local transcription; not Rev-equivalent; transcript-sensitive wording remains qualified |
| SRC-TR-OPEN | MA v. Lindsay Clancy Opening Statements | Rev.pdf | Mixed same-day source; EV-MED-0031/0033 rely on later Patrick Clancy testimony, not counsel's opening argument | MIXED SOURCE — opening statements are not evidence; later witness testimony is evidentiary when specifically timestamped and atom-classified. |
Day 21 provenance control. MED-PRE v1.1 was sealed using the local Whisper source conservatively. Publication-critical classifications do not depend on a transcript-sensitive Day 21 word or negation. A Rev Day 21 working transcript became public on August 27, 2026 and is now preserved as a higher-authority working source for later reconciliation. The sealed v1.1 source state is not silently rewritten after the fact.
LIMITATIONS & OPEN QUESTIONS
Unknown is a valid result.
- Trial testimony may summarize underlying records that are not independently reproduced in full.
- Toxicology attribution can be limited by exact medication-administration and specimen timing.
- Pill counts constrain but do not prove ingestion.
- Exact January 16 diazepam 2 mg quantity/SIG remains open.
- South Shore emergency medication-administration timing relative to toxicology draw remains open.
- Exact 2022 Prozac quantity/duration remains open.
- Exact Buspar/hydroxyzine dose chronology remains open.
- Exact day-by-day Seroquel dosing remains open.
- Underlying Apple Watch/Health data for reported heart-rate fluctuation remain open.
- Primary-record exposure, if any, to Abilify or Lexapro remains open.
- Remaining prescription-date versus fill-date distinctions remain open.
- Final Rev/audio reconciliation of the Day 21 Lamictal wording remains open.
- The temporal locus of the Day 21 lithium reference remains open.
VERSION & CORRECTION LAW
No silent overwrite.
v1.0August 27, 2026Historical frozen source-state before Day 21 reconciliation and final validation closure.
v1.1August 27, 2026Final validated source-state authorized for publication preparation. Independent validation, clause-level traceability, publication-readiness QC, citation-map normalization, and source-map QC are closed.
New evidence that narrows a bounded gap without materially changing the central corpus creates a v1.x amendment. Newly authenticated evidence that materially changes a major finding triggers a major-version review rather than silent replacement.
WHAT THIS AUDIT DOES NOT DECIDE
Evidence reconstruction is not a causal verdict.
This audit does not decide diagnosis, criminal responsibility, lack of criminal responsibility, malpractice, whether medication caused the homicides, or whether a reported subjective symptom was true merely because the report occurred. Provider response is not automatic confirmation of an originating claim. Expert interpretation remains attributed. Attorney argument is not evidence.
The public proof is the work: finding → Evidence ID → Source ID → pinpoint → limitation → unresolved status → version history.
With love. Always. ♥️ -Stevie Belfiore